Supernus Pharmaceuticals Inc (SUPN)

Activity ratios

Short-term

Turnover ratios

Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Inventory turnover 4.15 5.02 5.02 5.13 5.11 5.88 5.20 4.67 4.45 5.66 5.59 5.74 5.35 5.22 5.40 7.34 6.64 7.18 7.03 6.85
Receivables turnover — 4.37 4.70 4.70 4.07 3.97 3.91 4.04 3.76 4.08 4.02 4.22 3.60 3.50 3.31 3.37 4.50 4.71 4.84 5.05
Payables turnover — 123.56 103.37 40.54 44.34 30.54 12.41 33.64 40.98 37.30 45.15 48.40 42.09 19.80 34.58 57.35 17.42 59.25 44.82 25.09
Working capital turnover 2.98 3.83 3.75 4.45 14.57 — — 2.06 1.96 1.26 1.55 1.55 1.32 1.84 1.45 1.03 1.26 1.47 1.66 1.51

1. Inventory Turnover:
- Supernus Pharmaceuticals Inc's inventory turnover has been relatively stable over the quarters, ranging between 0.95 and 1.08. This indicates that the company is able to sell and replace its inventory approximately once a year, with a slight improvement in the most recent quarter.

2. Receivables Turnover:
- The receivables turnover ratio has also been consistent, fluctuating between 4.03 and 4.66 over the past eight quarters. This suggests that Supernus Pharmaceuticals Inc is efficient in collecting payments from its customers, with a higher ratio indicating quicker collections.

3. Payables Turnover:
- The payables turnover ratio has shown significant fluctuations, with a notable increase in Q4 2023 compared to the previous quarters. This may indicate that the company is taking longer to pay its suppliers, which could have both positive and negative implications depending on the specific circumstances.

4. Working Capital Turnover:
- The working capital turnover ratio has been more variable, with a significant decrease in Q4 2022 followed by an increase in the most recent quarters. This ratio measures how effectively the company is using its working capital to generate sales revenue, and the recent increase suggests improved efficiency in this aspect.

Overall, Supernus Pharmaceuticals Inc's activity ratios provide insights into how the company manages its inventory, receivables, payables, and working capital to support its operational activities. Continued monitoring and analysis of these ratios can help investors and analysts assess the company's operational efficiency and financial health.

Average number of days

Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Days of inventory on hand (DOH) days 88.01 72.76 72.67 71.09 71.48 62.06 70.26 78.19 82.04 64.52 65.31 63.61 68.18 69.94 67.63 49.75 55.01 50.85 51.93 53.28
Days of sales outstanding (DSO) days — 83.54 77.74 77.66 89.75 91.96 93.33 90.44 97.06 89.52 90.85 86.43 101.48 104.40 110.39 108.16 81.16 77.52 75.45 72.24
Number of days of payables days — 2.95 3.53 9.00 8.23 11.95 29.41 10.85 8.91 9.79 8.09 7.54 8.67 18.44 10.55 6.36 20.95 6.16 8.14 14.55

Days of Inventory on Hand (DOH) measures how efficiently a company manages its inventory. A decreasing trend in DOH from Q1 2022 to Q4 2023 indicates that Supernus Pharmaceuticals Inc has been able to reduce the number of days it holds inventory on hand to generate sales.

Days of Sales Outstanding (DSO) reflects the average number of days it takes for the company to collect payment after making a sale. A decreasing trend in DSO from Q1 2022 to Q4 2023 suggests that Supernus Pharmaceuticals Inc has been improving its collection process and receiving payments from customers more quickly.

Number of Days of Payables measures how long a company takes to pay its suppliers. Supernus Pharmaceuticals Inc shows fluctuating trends in the number of days of payables, with an increasing trend from Q1 2022 to Q3 2022, followed by a decline in Q4 2022 and a further decrease in Q1 2023. This indicates changes in the company's payment terms or its ability to manage supplier payments effectively.

Overall, the activity ratios suggest that Supernus Pharmaceuticals Inc has been enhancing its operational efficiency by managing inventory levels, improving receivables collection, and adjusting payment terms with suppliers.

Long-term

Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Fixed asset turnover 605,106.00 45.25 45.20 46.18 44.36 41.03 37.89 34.03 33.03 33.09 32.32 14.14 13.40 26.75 23.33 22.33 23.01 40.92 101.56 95.58
Total asset turnover 605,106.00 0.48 0.50 0.38 0.40 0.38 0.36 0.36 0.33 0.35 0.35 0.36 0.34 0.31 0.28 0.34 0.34 0.37 0.38 0.39

The fixed asset turnover ratio measures how efficiently a company is using its fixed assets to generate sales. In the case of Supernus Pharmaceuticals Inc, the fixed asset turnover ratio has been consistently high, ranging from 34.93 to 45.75 over the past eight quarters. This indicates that the company is generating a high level of sales relative to its investment in fixed assets, which is a positive sign of operational efficiency.

The total asset turnover ratio reflects how well a company is utilizing all its assets to generate sales. Supernus Pharmaceuticals Inc's total asset turnover ratio has remained relatively stable, ranging from 0.37 to 0.49 over the same period. This suggests that the company is effectively leveraging both its fixed and current assets to generate revenue.

Overall, the high fixed asset turnover ratio combined with the stable total asset turnover ratio indicates that Supernus Pharmaceuticals Inc is effectively managing its assets and generating sales efficiently. This bodes well for the company's long-term financial performance and operational success.